Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 10Phase NA 3Phase 1/2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 265Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 174Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 130Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

Temozolomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Adenoma, Islet Cell × Clear all
NCT00576680 2020-07-09

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1/2 Completed
43 enrolled 8 charts

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡